SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Attention is centered on reports that Papa Johns largest U.S. franchisee has joined Irth Capitals effort to take the company private, reviving buyout hopes. Traders see the franchisees involvement as strengthening the proposal, while others remain skeptical that the board will approve a deal or that negotiations will produce a signed transaction.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks rallied with cybersecurity peers as traders focused on an Evercore ISI survey indicating enterprise security budgets are firming and on escalating vulnerability and AI-driven cyberthreat concerns. The move drew bullish momentum commentary, while some traders questioned whether the sectors gains are justified given lofty valuations.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Phase 3 results for Amgens IMDELLTRA-plus-IMFINZI combination in extensive-stage small-cell lung cancerreported to reduce the risk of death by 58%are driving discussion, with traders viewing the data as a potential growth opportunity. Some also point to Repathas sales growth as a key business driver and debate whether the lung-cancer program can become a major contributor.

TOSHI

TOSHI is drawing attention around a hoped-for breakout after bursts of volume and a modest rebound, with traders repeatedly watching a stubborn resistance zone and speculating about a short squeeze. Bulls are accumulating and anticipating a run, while skeptics point to repeated rejections, weak price action, and broader crypto-market risk; rumors of listings or an announcement remain unconfirmed.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 breast-cancer study are driving discussion, with traders highlighting favorable efficacy for gedatolisib and the potential for a PIK3CA-mutant label expansion. The reaction is split between enthusiasm for the data and concern that CELC still needs to demonstrate commercial uptake and revenue; some posts also debate whether the share price reflects the clinical results.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Promising lung-cancer trial updates for BioNTechs oncology pipeline, including pumitamig and gotistobart, are drawing attention, with traders highlighting encouraging response and survival data. The reaction is bullish but tempered by questions about how durable the results are and lingering concerns over earlier clinical setbacks and leadership changes.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare shares are drawing attention after a sharp gain tied to the PHP2Shell web-software vulnerabilities: traders see its web application firewall as a potential beneficiary as site operators seek protection, alongside a broader cybersecurity-stock rally. Some participants are bullish on the security-demand angle, while others focus on the stocks high valuation and trade the move cautiously.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, unexplained XCN price spike is drawing attention, with traders noting a large candle and a reported surge before any clear news catalyst. The reaction is divided between dip-buyers expecting a rebound and skeptics calling the repeated spikes and quick reversals pump-and-dump behavior; some also link moves to Bitcoin and broader crypto conditions.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

A broad biotech-sector pullback is the main focus, with IBB hovering near its 50-day moving average after a strong run. Traders describe the dip as a pause while others remain cautious about sector weakness, and several note that large-cap biotech is holding up better than smaller names.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Attention centers on Merck and Modernas Phase 3 melanoma-vaccine results: the personalized vaccine combined with Keytruda met trial endpoints, but traders debate whether the benefit and future commercial potential justify expectations, with some viewing the share pullback as a sell the news reaction. The treatment is not yet approved, and its broader use remains uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround 

X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial

(RTTNews) - X4 Pharmaceuticals (XFOR) announced positive outcome of Type C Meeting with the
FDA related to the global 4WARD Phase 3 clinical trial. The purpose of the meeting was to gain alignment on a revised sample size and associated statistical power and the size of the safe...

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now...

X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative...

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

Equity

Bullish Sentiment

X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations">said.</a> The strategic restructuring is aimed at aligning resources to complete the late-stage trial of Mavorixafor in patients with moderate and severe chronic neutropenia, it added.Shares of the company traded 0.5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/XFOR">XFOR stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.The Boston-headquartered firm announced that Chief Legal and Compliance Officer Natasha Thoren, Chief Operating Officer Mary DiBiase, and Chief Commercial Officer Mark Baldry will be exiting the company as part of the workforce reduction. Chief Medical Officer Christophe Arbet‑Engels, meanwhile, is resigning for personal reasons, it added.“Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well-positioned to become a world‑class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia,” said Executive Chairman Adam Craig.The company also appointed its President, John Volpone, as the COO, and he will now oversee day‑to‑day operational management and business execution in his expanded role. Craig, meanwhile, will oversee clinical development.The company’s Mavorixafor is marketed as Xolremdi in the U.S. for the treatment of people aged 12 years and older with WHIM syndrome — a rare, primary immunodeficiency disorder that impairs white blood cell movement from the bone marrow to the bloodstream. The company is now evaluating additional uses of Mavorixafor and is conducting a global, pivotal late-stage clinical trial in people with certain chronic neutropenic disorders. Neutropenia is characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections.XFOR stock is down by about 85% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.

ProShares UltraPro Russell2000

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.24
Prev Close	$3.20
Open	$3.16
Dividend Yield	0.00%
50-Day Moving Average	$3.41
Beta	1.53
Avg. Volume	1.23M
PE Ratio	-2.71

52-Week High	$4.83
52-Week Low	$2.43
Market Capitalization	$321.24M
EPS (Annual)	-$1.87
Price to Book	2.00
Revenue Per Employee	$780,288.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

XFOR Fundamentals